Stellar Biotechnologies reports $1.1 million loss for quarter
Stellar Biotechnologies, based in Port Hueneme, reported drops in both revenues and expenses for the quarter ended March 31. Revenues decreased 81 percent from $330,000 during the same quarter the previous year to $60,000 for the most recent quarter. The immunotherapy developer and manufacturer attributed the decrease to lower sales volume for pre-clinical studies, compared Read More →
Inogen’s profits just keep on growing
Goleta-based Inogen, an oxygen concentrator company, reported a $5.9 million profit for the first quarter of 2017, up from $2.5 million in the first quarter of 2016, according to an earnings report May 9. The company reported $52.5 million in revenue, up 22.1 percent from the same period in 2016. Sales revenue was at $46 Read More →
Sientra narrows losses in first quarter report
Goleta-based breast implant company Sientra continued to cut its losses, losing $11.4 million in the first quarter of 2017, down from $11.9 million for the same period the year prior. “I am pleased with our first quarter performance, which was in line or above our expectations,” said Jeffrey Nugent, chairman and CEO. “In the first Read More →
MindBody revenue soars but net loss continues
San Luis Obispo-based MindBody reported $42.2 million in first quarter revenue, a 32 percent increase from a year ago during the same period, but the company still reported a net loss. The GAAP net loss in the first quarter of 2017 was $3.9 million, down from $6.6 million during the first quarter of 2016. The Read More →
Amgen to provide rebates for Repatha patients who have heart attack or stroke
Thousand Oaks-based Amgen announced on May 2 that it has reached a “first-of-its-kind contract” with health care company Harvard Pilgrim. The contract provides Harvard Pilgrim with a rebate for the cost of Repatha for any eligible patient who has a heart attack or stroke while on Repatha. “Amgen is committed to combating cardiovascular disease, one Read More →
Amgen revenues fall but profits increase
Thousand Oaks-based biotech giant Amgen’s total revenues decreased by 1 percent to $5.5 billion during the first quarter of 2017, compared to the same period a year ago, according to an earnings report April 26. The drop was related to the plunge in sales of Enbrel, its rheumatoid arthritis drug. Sales decreased 15 percent due Read More →
Cottage Health settles flesh-eating disease death lawsuit
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
